$10.9 Billion Attention Deficit Hyperactivity Disorder (ADHD) Opportunity Assessment and Forecasts 2022-2024 & 2032: Epidemiology, Symptoms, Diagnosis, Disease Management, Revenue, Unmet N...
Cingulate Inc. (CING)
Company Research
Source: Yahoo! Finance
The ADHD therapeutics market, valued at $11.9 billion in the 2022 baseline year, is expected to encounter a negative compound annual growth rate (CAGR) of 0.9%, ultimately reaching an estimated $10.9 billion by 2032. This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Attention Deficit Hyperactivity Disorder (ADHD) market through 2032. The prevalent cases of ADHD in the 7MM will increase from 21,141,036 to 21,970,997, at an annual growth rate (AGR) of 0.4% over the forecast period. The ADHD market was valued at $11.9 billion in the 2022 baseline year. Over the 10-year forecast period, the market is projected to decline at a negative compound annual growth rate (CAGR) of 0.9%, to $10.9 billion by 2032. The major driver for this decline is patent expiry and entry of cheap generic alternatives of branded products within the forecast period. In addition, the market has been heavily affected by shortages of act
Show less
Read more
Impact Snapshot
Event Time:
CING
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CING alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CING alerts
High impacting Cingulate Inc. news events
Weekly update
A roundup of the hottest topics
CING
News
- Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access EventGlobeNewswire
- Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance [Yahoo! Finance]Yahoo! Finance
- Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing ClearanceGlobeNewswire
- FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD [Yahoo! Finance]Yahoo! Finance
- FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHDGlobeNewswire
CING
Sec Filings
- 6/18/24 - Form PRE
- 6/18/24 - Form 8-K
- 6/13/24 - Form 4
- CING's page on the SEC website